Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $20.83.

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now directly owns 35,142 shares of the company’s stock, valued at $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the completion of the sale, the insider now owns 47,332 shares in the company, valued at $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 over the last ninety days. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Lynx1 Capital Management LP increased its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. RTW Investments LP increased its position in shares of Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares during the last quarter. State Street Corp lifted its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics in the second quarter worth approximately $19,835,000. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the period.

Stoke Therapeutics Stock Down 8.2 %

Shares of STOK stock opened at $11.11 on Thursday. The business’s fifty day moving average is $12.49 and its 200 day moving average is $13.60. The stock has a market cap of $588.46 million, a price-to-earnings ratio of -5.29 and a beta of 0.95. Stoke Therapeutics has a twelve month low of $4.09 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Equities research analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.